logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 4 of 4 Items
Showing 1 - 4 of 4 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Outcomes of AIDS-associated Kaposi sarcoma in Mozambique after treatment with pegylated liposomal doxorubicin

Coldiron ME, Gutierrez Zamudio AG, Manuel R, Luciano G, Rusch B,  et al.
2021-01-07 • Infectious Agents and Cancer
2021-01-07 • Infectious Agents and Cancer
BACKGROUND
Kaposi’s sarcoma (KS) is a common HIV-associated malignancy frequently associated with poor outcomes. It is the most frequently diagnosed cancer in major cities of Mozambi...
Journal Article
|
Research

Assessing the outcomes of HIV-infected persons receiving treatment for Kaposi sarcoma in Conakry-Guinea

Bekolo CE, Soumah MM, Tiemtore OW, Diallo AK, Yuma JD,  et al.
2017-12-02 • BMC Cancer
2017-12-02 • BMC Cancer
BACKGROUND
Médecins Sans Frontières is supporting comprehensive HIV care and treatment for Kaposi Sarcoma (KS) in Guinea, where antiretroviral coverage is low and access to KS treatm...
Conference Material
|
Video

Improved outcomes for Kaposi sarcoma using pegylated liposomal doxorubicin

Coldiron ME
2021-06-10 • Epicentre Scientific Day Paris 2021
2021-06-10 • Epicentre Scientific Day Paris 2021
Conference Material
|
Abstract

Improved outcomes for Kaposi sarcoma using pegylated liposomal doxorubicin

Coldiron ME
2021-06-10 • Epicentre Scientific Day Paris 2021
2021-06-10 • Epicentre Scientific Day Paris 2021
BACKGROUND
Kaposi’s sarcoma (KS) is an HIV-associated malignancy associated with poor outcomes. Antiretroviral therapy (ART) is the cornerstone of KS treatment, but many patients req...